Skip to content

LBRX LBRX Total Equity

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Alkermes logo
AlkermesALKS
$1.75B+15.9%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$399.83M+285%
Alto Neuroscience logo
Alto NeuroscienceANRO
$243.37M+75.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$205.8M+402%
Opko Health logo
Opko HealthOPK
$1.2B-8.2%

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's total equity?
LBRX (LBRX) reported total equity of $378.69M in Q1 2026.
How has LBRX's total equity changed year-over-year?
LBRX's total equity increased by 481.2% year-over-year, from -$99.34M to $378.69M.
What is the long-term trend for LBRX's total equity?
Over 2 years (2023 to 2025), LBRX's total equity has grown at a 195.6% compound annual growth rate (CAGR), from -$34.47M to $301.31M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.